AR048962A1 - Combinaciones de 1- fenil-1,5 - dihidro - pirido - (3,2-b) indol -2- onas sustituidas y otros inhibidores de vih - Google Patents
Combinaciones de 1- fenil-1,5 - dihidro - pirido - (3,2-b) indol -2- onas sustituidas y otros inhibidores de vihInfo
- Publication number
- AR048962A1 AR048962A1 ARP050102016A ARP050102016A AR048962A1 AR 048962 A1 AR048962 A1 AR 048962A1 AR P050102016 A ARP050102016 A AR P050102016A AR P050102016 A ARP050102016 A AR P050102016A AR 048962 A1 AR048962 A1 AR 048962A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- amino
- inhibitors
- mono
- dpc963
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 15
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title 1
- -1 methanimidamidyl Chemical group 0.000 abstract 25
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 17
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 abstract 10
- ILAYIAGXTHKHNT-UHFFFAOYSA-N 4-[4-(2,4,6-trimethyl-phenylamino)-pyrimidin-2-ylamino]-benzonitrile Chemical compound CC1=CC(C)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 ILAYIAGXTHKHNT-UHFFFAOYSA-N 0.000 abstract 7
- HSBKFSPNDWWPSL-CAHLUQPWSA-N 4-amino-5-fluoro-1-[(2r,5s)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one Chemical class C1=C(F)C(N)=NC(=O)N1[C@H]1C=C[C@@H](CO)O1 HSBKFSPNDWWPSL-CAHLUQPWSA-N 0.000 abstract 7
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 7
- UXCAQJAQSWSNPQ-XLPZGREQSA-N Alovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](F)C1 UXCAQJAQSWSNPQ-XLPZGREQSA-N 0.000 abstract 6
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 abstract 6
- RLAHNGKRJJEIJL-RFZPGFLSSA-N [(2r,4r)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@H]1CO[C@@H](CO)O1 RLAHNGKRJJEIJL-RFZPGFLSSA-N 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 abstract 6
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 abstract 6
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 abstract 6
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 abstract 6
- 125000001424 substituent group Chemical group 0.000 abstract 6
- UXDWYQAXEGVSPS-GFUIURDCSA-N (4s)-6-chloro-4-[(e)-2-cyclopropylethenyl]-4-(trifluoromethyl)-1,3-dihydroquinazolin-2-one Chemical compound C(/[C@]1(C2=CC(Cl)=CC=C2NC(=O)N1)C(F)(F)F)=C\C1CC1 UXDWYQAXEGVSPS-GFUIURDCSA-N 0.000 abstract 5
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 abstract 5
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 abstract 5
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 abstract 5
- 229960004748 abacavir Drugs 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 5
- 229960004525 lopinavir Drugs 0.000 abstract 5
- 229960000311 ritonavir Drugs 0.000 abstract 5
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 abstract 5
- HSBKFSPNDWWPSL-VDTYLAMSSA-N 4-amino-5-fluoro-1-[(2s,5r)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one Chemical compound C1=C(F)C(N)=NC(=O)N1[C@@H]1C=C[C@H](CO)O1 HSBKFSPNDWWPSL-VDTYLAMSSA-N 0.000 abstract 4
- 108010032976 Enfuvirtide Proteins 0.000 abstract 4
- 235000008529 Ziziphus vulgaris Nutrition 0.000 abstract 4
- 244000126002 Ziziphus vulgaris Species 0.000 abstract 4
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 229960002062 enfuvirtide Drugs 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 4
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 abstract 4
- YIBOMRUWOWDFLG-ONEGZZNKSA-N rilpivirine Chemical compound CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-ONEGZZNKSA-N 0.000 abstract 4
- 229960004556 tenofovir Drugs 0.000 abstract 4
- SUJUHGSWHZTSEU-FYBSXPHGSA-N tipranavir Chemical compound C([C@@]1(CCC)OC(=O)C([C@H](CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)=C(O)C1)CC1=CC=CC=C1 SUJUHGSWHZTSEU-FYBSXPHGSA-N 0.000 abstract 4
- SPZFCKVVHXRLAI-XOCWCZJOSA-N (3s,4s)-4-[8-[[(1r,3as,5ar,5br,7ar,9s,11ar,11br,13ar,13br)-9-hydroxy-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carbonyl]amino]octanoylamino]-3-hydroxy-6-methylheptanoic acid Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC[C@]1(C)[C@@H]2CC[C@@H]2[C@H]3[C@H](C(C)=C)CC[C@]3(C(=O)NCCCCCCCC(=O)N[C@@H](CC(C)C)[C@@H](O)CC(O)=O)CC[C@]21C SPZFCKVVHXRLAI-XOCWCZJOSA-N 0.000 abstract 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 3
- 125000005988 1,1-dioxo-thiomorpholinyl group Chemical group 0.000 abstract 3
- 125000005987 1-oxo-thiomorpholinyl group Chemical group 0.000 abstract 3
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 abstract 3
- 108010019625 Atazanavir Sulfate Proteins 0.000 abstract 3
- 108010036239 CD4-IgG(2) Proteins 0.000 abstract 3
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 abstract 3
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 abstract 3
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 abstract 3
- SUJUHGSWHZTSEU-UHFFFAOYSA-N Tipranavir Natural products C1C(O)=C(C(CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)C(=O)OC1(CCC)CCC1=CC=CC=C1 SUJUHGSWHZTSEU-UHFFFAOYSA-N 0.000 abstract 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 3
- 229950005846 amdoxovir Drugs 0.000 abstract 3
- 229960001830 amprenavir Drugs 0.000 abstract 3
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 abstract 3
- 229960003277 atazanavir Drugs 0.000 abstract 3
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 229960005107 darunavir Drugs 0.000 abstract 3
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 abstract 3
- 229960005319 delavirdine Drugs 0.000 abstract 3
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 abstract 3
- 229960003804 efavirenz Drugs 0.000 abstract 3
- 229960002049 etravirine Drugs 0.000 abstract 3
- PYGWGZALEOIKDF-UHFFFAOYSA-N etravirine Chemical compound CC1=CC(C#N)=CC(C)=C1OC1=NC(NC=2C=CC(=CC=2)C#N)=NC(N)=C1Br PYGWGZALEOIKDF-UHFFFAOYSA-N 0.000 abstract 3
- LLYJISDUHFXOHK-GOCONZMPSA-N ferroptocide Chemical compound C[C@@H]1CC[C@@]23C[C@@H](C(=O)[C@]2([C@@]1([C@@H](C[C@H]([C@@H]3C)C4=CCN5C(=O)N(C(=O)N5C4)C6=CC=CC=C6)OC(=O)CCl)C)O)O LLYJISDUHFXOHK-GOCONZMPSA-N 0.000 abstract 3
- 229960003142 fosamprenavir Drugs 0.000 abstract 3
- MLBVMOWEQCZNCC-OEMFJLHTSA-N fosamprenavir Chemical compound C([C@@H]([C@H](OP(O)(O)=O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 MLBVMOWEQCZNCC-OEMFJLHTSA-N 0.000 abstract 3
- 125000002883 imidazolyl group Chemical group 0.000 abstract 3
- 229960001936 indinavir Drugs 0.000 abstract 3
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 abstract 3
- 125000001786 isothiazolyl group Chemical group 0.000 abstract 3
- 125000000842 isoxazolyl group Chemical group 0.000 abstract 3
- 125000002757 morpholinyl group Chemical group 0.000 abstract 3
- 229960000884 nelfinavir Drugs 0.000 abstract 3
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 abstract 3
- 229960000689 nevirapine Drugs 0.000 abstract 3
- 239000002777 nucleoside Substances 0.000 abstract 3
- 125000001715 oxadiazolyl group Chemical group 0.000 abstract 3
- 125000002971 oxazolyl group Chemical group 0.000 abstract 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 abstract 3
- 125000004193 piperazinyl group Chemical group 0.000 abstract 3
- 125000003386 piperidinyl group Chemical group 0.000 abstract 3
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 3
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 3
- 229960001852 saquinavir Drugs 0.000 abstract 3
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 abstract 3
- 125000001113 thiadiazolyl group Chemical group 0.000 abstract 3
- 125000000335 thiazolyl group Chemical group 0.000 abstract 3
- 125000004568 thiomorpholinyl group Chemical group 0.000 abstract 3
- 229960000838 tipranavir Drugs 0.000 abstract 3
- 125000001425 triazolyl group Chemical group 0.000 abstract 3
- NIDRYBLTWYFCFV-FMTVUPSXSA-N (+)-calanolide A Chemical compound C1=CC(C)(C)OC2=C1C(O[C@H](C)[C@@H](C)[C@@H]1O)=C1C1=C2C(CCC)=CC(=O)O1 NIDRYBLTWYFCFV-FMTVUPSXSA-N 0.000 abstract 2
- JFKIHXVQWVFSNI-FCJVTMLMSA-N (2r,3r,4r,5r,6r,7r)-3,6-bis[(3-aminophenyl)methoxy]-2,7-dibenzyl-1,1-dioxothiepane-4,5-diol Chemical compound NC1=CC=CC(CO[C@H]2[C@H](S(=O)(=O)[C@H](CC=3C=CC=CC=3)[C@H](OCC=3C=C(N)C=CC=3)[C@H](O)[C@H]2O)CC=2C=CC=CC=2)=C1 JFKIHXVQWVFSNI-FCJVTMLMSA-N 0.000 abstract 2
- IXZYCIFRVZKVRJ-RKKDRKJOSA-N (2s)-n-[(2s,3r)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]-2-[[2-[(3-fluorophenyl)methylamino]acetyl]amino]-3,3-dimethylbutanamide Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)[C@@H](NC(=O)CNCC=1C=C(F)C=CC=1)C(C)(C)C)C1=CC=CC=C1 IXZYCIFRVZKVRJ-RKKDRKJOSA-N 0.000 abstract 2
- SPZFCKVVHXRLAI-ZGEYYWTRSA-N (3r,4s)-4-[8-[[(1r,3as,5ar,5br,7ar,9s,11ar,11br,13ar,13br)-9-hydroxy-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carbonyl]amino]octanoylamino]-3-hydroxy-6-methylheptanoic acid Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC[C@]1(C)[C@@H]2CC[C@@H]2[C@H]3[C@H](C(C)=C)CC[C@]3(C(=O)NCCCCCCCC(=O)N[C@@H](CC(C)C)[C@H](O)CC(O)=O)CC[C@]21C SPZFCKVVHXRLAI-ZGEYYWTRSA-N 0.000 abstract 2
- XCVGQMUMMDXKCY-WZJLIZBTSA-N (4R,5S,6S,7R)-4,7-dibenzyl-5,6-dihydroxy-1,3-bis[4-(hydroxymethyl)benzyl]-1,3-diazepan-2-one Chemical compound C1=CC(CO)=CC=C1CN1C(=O)N(CC=2C=CC(CO)=CC=2)[C@H](CC=2C=CC=CC=2)[C@H](O)[C@@H](O)[C@H]1CC1=CC=CC=C1 XCVGQMUMMDXKCY-WZJLIZBTSA-N 0.000 abstract 2
- CUFQBQOBLVLKRF-RZDMPUFOSA-N (4r)-3-[(2s,3s)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylbutanoyl]-5,5-dimethyl-n-[(2-methylphenyl)methyl]-1,3-thiazolidine-4-carboxamide Chemical compound CC1=CC=CC=C1CNC(=O)[C@@H]1C(C)(C)SCN1C(=O)[C@@H](O)[C@@H](NC(=O)C=1C(=C(O)C=CC=1)C)CC1=CC=CC=C1 CUFQBQOBLVLKRF-RZDMPUFOSA-N 0.000 abstract 2
- KYRSNWPSSXSNEP-ZRTHHSRSSA-N (4r,5s,6s,7r)-1,3-bis[(3-aminophenyl)methyl]-4,7-dibenzyl-5,6-dihydroxy-1,3-diazepan-2-one Chemical compound NC1=CC=CC(CN2C(N(CC=3C=C(N)C=CC=3)[C@H](CC=3C=CC=CC=3)[C@H](O)[C@@H](O)[C@H]2CC=2C=CC=CC=2)=O)=C1 KYRSNWPSSXSNEP-ZRTHHSRSSA-N 0.000 abstract 2
- JJWJSIAJLBEMEN-ZDUSSCGKSA-N (4s)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1,3-dihydroquinazolin-2-one Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)N1)C(F)(F)F)#CC1CC1 JJWJSIAJLBEMEN-ZDUSSCGKSA-N 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- OXCBPKZYTDEQDL-UHFFFAOYSA-N 2-(2-benzyl-1,1,3-trioxothieno[3,4-e][1,2,4]thiadiazin-4-yl)acetonitrile Chemical compound O=C1N(CC#N)C2=CSC=C2S(=O)(=O)N1CC1=CC=CC=C1 OXCBPKZYTDEQDL-UHFFFAOYSA-N 0.000 abstract 2
- GSNHKUDZZFZSJB-HLMSNRGBSA-N 4,4-Difluoro-N-[(1S)-3-[(1R,5S)-3-[3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboximidic acid Chemical compound CC(C)C1=NN=C(C)N1C1C[C@H](N2CC[C@H](NC(=O)C3CCC(F)(F)CC3)C=3C=CC=CC=3)CC[C@H]2C1 GSNHKUDZZFZSJB-HLMSNRGBSA-N 0.000 abstract 2
- VIBQRYBYKVEMJI-YSIASYRMSA-N 4-[[(2s,3s)-4-[(4r)-4-(tert-butylcarbamoyl)-5,5-dimethyl-1,3-thiazolidin-3-yl]-3-hydroxy-4-oxo-1-phenylbutan-2-yl]amino]-2,2-dimethyl-4-oxobutanoic acid Chemical compound C1SC(C)(C)[C@@H](C(=O)NC(C)(C)C)N1C(=O)[C@@H](O)[C@@H](NC(=O)CC(C)(C)C(O)=O)CC1=CC=CC=C1 VIBQRYBYKVEMJI-YSIASYRMSA-N 0.000 abstract 2
- ZNFFMCYSMBXZQU-NSHDSACASA-N 5-chloro-8-methyl-7-(3-methyl-but-2-enyl)-6,7,8,9-tetrahydro-2h-2,7,9a-triaza-benzo[cd]azulene-1-thione Chemical compound C1N(CC=C(C)C)[C@@H](C)CN2C(=S)NC3=CC=C(Cl)C1=C32 ZNFFMCYSMBXZQU-NSHDSACASA-N 0.000 abstract 2
- ATCRIOJPQXDFNY-ZETCQYMHSA-N 6-chloro-2-(1-furo[2,3-c]pyridin-5-yl-ethylsulfanyl)-pyrimidin-4-ylamine Chemical compound S([C@@H](C)C=1N=CC=2OC=CC=2C=1)C1=NC(N)=CC(Cl)=N1 ATCRIOJPQXDFNY-ZETCQYMHSA-N 0.000 abstract 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract 2
- NIDRYBLTWYFCFV-IUUKEHGRSA-N Calanolide A Natural products C1=CC(C)(C)OC2=C1C(O[C@H](C)[C@H](C)[C@@H]1O)=C1C1=C2C(CCC)=CC(=O)O1 NIDRYBLTWYFCFV-IUUKEHGRSA-N 0.000 abstract 2
- NJBBLOIWMSYVCQ-VZTVMPNDSA-N Kynostatin 272 Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)COC=1C2=CC=NC=C2C=CC=1)CSC)[C@H](O)C(=O)N1[C@@H](CSC1)C(=O)NC(C)(C)C)C1=CC=CC=C1 NJBBLOIWMSYVCQ-VZTVMPNDSA-N 0.000 abstract 2
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 abstract 2
- 229950004424 alovudine Drugs 0.000 abstract 2
- 125000005021 aminoalkenyl group Chemical group 0.000 abstract 2
- RYMCFYKJDVMSIR-RNFRBKRXSA-N apricitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1S[C@H](CO)OC1 RYMCFYKJDVMSIR-RNFRBKRXSA-N 0.000 abstract 2
- YJEJKUQEXFSVCJ-WRFMNRASSA-N bevirimat Chemical compound C1C[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C YJEJKUQEXFSVCJ-WRFMNRASSA-N 0.000 abstract 2
- 239000004305 biphenyl Substances 0.000 abstract 2
- NIDRYBLTWYFCFV-UHFFFAOYSA-N calanolide F Natural products C1=CC(C)(C)OC2=C1C(OC(C)C(C)C1O)=C1C1=C2C(CCC)=CC(=O)O1 NIDRYBLTWYFCFV-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- MDZKJHQSJHYOHJ-UHFFFAOYSA-N crataegolic acid Natural products C1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MDZKJHQSJHYOHJ-UHFFFAOYSA-N 0.000 abstract 2
- 125000004966 cyanoalkyl group Chemical group 0.000 abstract 2
- 229950006497 dapivirine Drugs 0.000 abstract 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 abstract 2
- 229950006528 elvucitabine Drugs 0.000 abstract 2
- MLILORUFDVLTSP-UHFFFAOYSA-N emivirine Chemical compound O=C1NC(=O)N(COCC)C(CC=2C=CC=CC=2)=C1C(C)C MLILORUFDVLTSP-UHFFFAOYSA-N 0.000 abstract 2
- 125000002541 furyl group Chemical group 0.000 abstract 2
- 230000004927 fusion Effects 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 229950010245 ibalizumab Drugs 0.000 abstract 2
- KELNNWMENBUHNS-NSHDSACASA-N isopropyl (2s)-2-ethyl-7-fluoro-3-oxo-3,4-dihydroquinoxaline-1(2h)-carboxylate Chemical compound FC1=CC=C2NC(=O)[C@H](CC)N(C(=O)OC(C)C)C2=C1 KELNNWMENBUHNS-NSHDSACASA-N 0.000 abstract 2
- 108010075606 kynostatin 272 Proteins 0.000 abstract 2
- CJPLEFFCVDQQFZ-UHFFFAOYSA-N loviride Chemical compound CC(=O)C1=CC=C(C)C=C1NC(C(N)=O)C1=C(Cl)C=CC=C1Cl CJPLEFFCVDQQFZ-UHFFFAOYSA-N 0.000 abstract 2
- 229950006243 loviride Drugs 0.000 abstract 2
- 229960004710 maraviroc Drugs 0.000 abstract 2
- GSNHKUDZZFZSJB-QYOOZWMWSA-N maraviroc Chemical compound CC(C)C1=NN=C(C)N1[C@@H]1C[C@H](N2CC[C@H](NC(=O)C3CCC(F)(F)CC3)C=3C=CC=CC=3)CC[C@H]2C1 GSNHKUDZZFZSJB-QYOOZWMWSA-N 0.000 abstract 2
- MDZKJHQSJHYOHJ-LLICELPBSA-N maslinic acid Chemical compound C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MDZKJHQSJHYOHJ-LLICELPBSA-N 0.000 abstract 2
- 229950008798 mozenavir Drugs 0.000 abstract 2
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 abstract 2
- 125000003835 nucleoside group Chemical group 0.000 abstract 2
- 239000002773 nucleotide Substances 0.000 abstract 2
- 125000003729 nucleotide group Chemical group 0.000 abstract 2
- 229950006460 palinavir Drugs 0.000 abstract 2
- RXBWRFDZXRAEJT-SZNOJMITSA-N palinavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)C=1N=C2C=CC=CC2=CC=1)C(C)C)[C@H](O)CN1[C@@H](C[C@@H](CC1)OCC=1C=CN=CC=1)C(=O)NC(C)(C)C)C1=CC=CC=C1 RXBWRFDZXRAEJT-SZNOJMITSA-N 0.000 abstract 2
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 2
- 125000002098 pyridazinyl group Chemical group 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 2
- WTTIBCHOELPGFK-LBPRGKRZSA-N r82150 Chemical compound C1N(CC=C(C)C)[C@@H](C)CN2C(=S)NC3=CC=CC1=C32 WTTIBCHOELPGFK-LBPRGKRZSA-N 0.000 abstract 2
- 229960004693 tenofovir disoproxil fumarate Drugs 0.000 abstract 2
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 2
- 125000001544 thienyl group Chemical group 0.000 abstract 2
- 229950011282 tivirapine Drugs 0.000 abstract 2
- 125000004306 triazinyl group Chemical group 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 229960000523 zalcitabine Drugs 0.000 abstract 2
- LGLVVVCSQBZONM-HCCLCSBVSA-N (2r)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentano Chemical compound NC(N)=NCCC[C@@H](NC(=O)C)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(N)=O LGLVVVCSQBZONM-HCCLCSBVSA-N 0.000 abstract 1
- PHIRWRJXMDCHJF-GBYUNDSOSA-N (2s)-1-[(2r)-2-[[(2r)-6-amino-2-[[(2r)-6-amino-2-[[2-[[2-[[2-[[2-[[2-(6-aminohexylamino)acetyl]-[3-(diaminomethylideneamino)propyl]amino]acetyl]-[3-(diaminomethylideneamino)propyl]amino]acetyl]-benzylamino]acetyl]-[3-(diaminomethylideneamino)propyl]amino] Chemical compound O=C([C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](CCCCN)NC(=O)CN(CCCN=C(N)N)C(=O)CN(C(=O)CN(CCCN=C(N)N)C(=O)CN(CCCN=C(N)N)C(=O)CNCCCCCCN)CC=1C=CC=CC=1)N1CCC[C@H]1C(N)=O PHIRWRJXMDCHJF-GBYUNDSOSA-N 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- BOLSWSQFGOVHCQ-UHFFFAOYSA-N 1-[(2,6-dichloropyridin-4-yl)methyl]-1,4,8,11-tetrazacyclotetradecane Chemical compound ClC1=NC(Cl)=CC(CN2CCNCCCNCCNCCC2)=C1 BOLSWSQFGOVHCQ-UHFFFAOYSA-N 0.000 abstract 1
- OKGPFTLYBPQBIX-CQSZACIVSA-N 1-[(2r)-4-benzoyl-2-methylpiperazin-1-yl]-2-(4-methoxy-1h-pyrrolo[2,3-b]pyridin-3-yl)ethane-1,2-dione Chemical compound C1=2C(OC)=CC=NC=2NC=C1C(=O)C(=O)N([C@@H](C1)C)CCN1C(=O)C1=CC=CC=C1 OKGPFTLYBPQBIX-CQSZACIVSA-N 0.000 abstract 1
- CIGWUKCQEVXGHE-UHFFFAOYSA-N 1-phenyl-5h-pyrido[3,2-b]indol-2-one Chemical class O=C1C=CC=2NC3=CC=CC=C3C=2N1C1=CC=CC=C1 CIGWUKCQEVXGHE-UHFFFAOYSA-N 0.000 abstract 1
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 108010038168 CGP 64222 Proteins 0.000 abstract 1
- JDVVGAQPNNXQDW-WCMLQCRESA-N Castanospermine Natural products O[C@H]1[C@@H](O)[C@H]2[C@@H](O)CCN2C[C@H]1O JDVVGAQPNNXQDW-WCMLQCRESA-N 0.000 abstract 1
- JDVVGAQPNNXQDW-TVNFTVLESA-N Castinospermine Chemical compound C1[C@H](O)[C@@H](O)[C@H](O)[C@H]2[C@@H](O)CCN21 JDVVGAQPNNXQDW-TVNFTVLESA-N 0.000 abstract 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 abstract 1
- 108010056642 N-alpha-acetyl-nona-D-arginine amide acetate Proteins 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 229940124821 NNRTIs Drugs 0.000 abstract 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 abstract 1
- 206010038997 Retroviral infections Diseases 0.000 abstract 1
- 208000005074 Retroviridae Infections Diseases 0.000 abstract 1
- IBHARWXWOCPXCR-WELGVCPWSA-N [(2s,3s,5r)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl (2-decoxy-3-dodecylsulfanylpropyl) hydrogen phosphate Chemical compound C1[C@H](N=[N+]=[N-])[C@@H](COP(O)(=O)OCC(CSCCCCCCCCCCCC)OCCCCCCCCCC)O[C@H]1N1C(=O)NC(=O)C(C)=C1 IBHARWXWOCPXCR-WELGVCPWSA-N 0.000 abstract 1
- ZGDKVKUWTCGYOA-URGPHPNLSA-N [4-[4-[(z)-c-(4-bromophenyl)-n-ethoxycarbonimidoyl]piperidin-1-yl]-4-methylpiperidin-1-yl]-(2,4-dimethyl-1-oxidopyridin-1-ium-3-yl)methanone Chemical compound C=1C=C(Br)C=CC=1C(=N/OCC)\C(CC1)CCN1C(CC1)(C)CCN1C(=O)C1=C(C)C=C[N+]([O-])=C1C ZGDKVKUWTCGYOA-URGPHPNLSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000005100 aryl amino carbonyl group Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 229960000633 dextran sulfate Drugs 0.000 abstract 1
- VDALIBWXVQVFGZ-UHFFFAOYSA-N dimethyl-[[4-[[3-(4-methylphenyl)-8,9-dihydro-7h-benzo[7]annulene-6-carbonyl]amino]phenyl]methyl]-(oxan-4-yl)azanium;chloride Chemical compound [Cl-].C1=CC(C)=CC=C1C1=CC=C(CCCC(=C2)C(=O)NC=3C=CC(C[N+](C)(C)C4CCOCC4)=CC=3)C2=C1 VDALIBWXVQVFGZ-UHFFFAOYSA-N 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229960005102 foscarnet Drugs 0.000 abstract 1
- 229940125777 fusion inhibitor Drugs 0.000 abstract 1
- 230000013595 glycosylation Effects 0.000 abstract 1
- 238000006206 glycosylation reaction Methods 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 229940124524 integrase inhibitor Drugs 0.000 abstract 1
- 239000002850 integrase inhibitor Substances 0.000 abstract 1
- 229940112586 kaletra Drugs 0.000 abstract 1
- 229940121292 leronlimab Drugs 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- CWJJHESJXJQCJA-UHFFFAOYSA-N n-(pyridin-2-ylmethyl)-1-[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methanamine Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CNCC1=CC=CC=N1 CWJJHESJXJQCJA-UHFFFAOYSA-N 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 abstract 1
- 229960002169 plerixafor Drugs 0.000 abstract 1
- 229920000447 polyanionic polymer Polymers 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 108010043277 recombinant soluble CD4 Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 abstract 1
- 229960005314 suramin Drugs 0.000 abstract 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente se refiere a combinaciones de 1-fenil-1,5-dihidro-pirido-[3,2-B]indol-2-onas sustituidas y otros inhibidores de VIH. También se refiere a productos que comprenden un compuesto de la formula (1) y otro inhibidor de VIH, como una preparacion combinada para el uso simultáneo, separado o secuencial en el tratamiento de infecciones retrovirales tales como una infeccion por VIH, en particular, en el tratamiento de infecciones con retrovirus resistentes a multiples fármacos. Reivindicacion 1: Una combinacion antiviral que comprende (a) un compuesto de la formula (1), un N-oxido, sal, forma estereoisomérica, mezcla racémica, profármaco, éster o metabolito del mismo, en la cual n es 1, 2 o 3; R1 es H, ciano, halo, aminocarbonilo, hidroxicarbonilo, alquiloxicarbonilo C1-4, alquilcarbonilo C1-4, mono- o di(alquil C1-4)aminocarbonilo, arilaminocarbonilo, N-(aril)-N-(alquil C1-4)aminocarbonilo, metanimidamidilo, N-hidroxi-metanimidamidilo, mono- o di(alquil C1-4)metanimidamidilo, Het1 o Het2; R2 es H, alquilo C1-10, alquenilo C2-10, cicloalquilo C3-7, en donde dicho alquilo C1-10, alquenilo C2-10 y cicloalquilo C3-7 pueden estar opcionalmente sustituidos, cada uno en forma individual e independiente, con un sustituyente seleccionado del grupo integrado por ciano, NR4aR4b, pirrolidinilo, piperidinilo, homopiperidinilo, piperazinilo, 4-(alquil C1-4)-piperazinilo, morfolinilo, tiomorfolinilo, 1-oxotiomorfolinilo, 1,1-dioxo-tiomorfolinilo, arilo, furanilo, tienilo, pirrolilo, oxazolilo, tiazolilo, imidazolilo, isoxazolilo, isotiazolilo, pirazolilo, oxadiazolilo, tiadiazolilo, triazolilo, tetrazolilo, piridilo, pirimidinilo, pirazinilo, piridazinilo, triazinilo, hidroxicarbonilo, alquilcarbonilo C1-4, N(R4aR4b)carbonilo, alquiloxicarbonilo C1-4, pirrolidin-1-ilcarbonilo, piperidin-1-ilcarbonilo, homopiperidin-1-ilcarbonilo, piperazin-1-ilcarbonilo, 4-(alquil C1-4)-piperazin-1-ilcarbonilo, morfolin-1-ilcarbonilo, tiomorfolin- 1-ilcarbonilo, 1-oxotiomorfolin-1-ilcarbonilo y 1,1-dioxo-tiomorfolin-1-ilcarbonilo; R3 es nitro, ciano, amino, halo, hidroxi, alquiloxi C1-4, hidroxicarbonilo, aminocarbonilo, alquiloxicarbonilo C1-4, mono- o di(alquil C1-4)aminocarbonilo, alquilcarbonilo C1-4, metanimidamidilo, mono- o di(alquil C1-4)metanimidamidilo, N-hidroxi-metanimidamidilo o Het1; R4a es H, alquilo C1-4 o alquilo C1-4 sustituido con un sustituyente seleccionado del grupo integrado por amino, mono- o di(alquil C1- 4)amino, pirrolidinilo, piperidinilo, homopiperidinilo, piperazinilo, 4-(alquil C1-4)-piperazinilo, morfolinilo, tiomorfolinilo, 1-oxotiomorfolinilo y 1,1-dioxo-tiomorfolinilo; R4b es H, alquilo C1-4 o alquilo C1-4 sustituido con un sustituyente seleccionado del grupo integrado por amino, mono- o di(alquil C1-4)amino, pirrolidinilo, piperidinilo, homopiperidinilo, piperazinilo, 4-(alquil C1-4)-piperazinilo, morfolinilo, tiomorfolinilo, 1-oxotiomorfolinilo y 1,1-dioxo-tiomorfolinilo; arilo es fenilo opcionalmente sustituido con uno o más sustituyentes seleccionados, cada uno en forma individual, del grupo integrado por alquilo C1-6, alcoxi C1-4, halo, hidroxi, amino, trifluormetilo, ciano, nitro, hidroxialquilo C1-6, cianoalquilo C1- 6, mono- o di(alquil C1-4)amino, aminoalquilo C1-4, mono- o di(alquil C1-4)aminoalquilo C1-4; Het1 es un sistema anular de 5 miembros en donde uno, dos, tres o cuatro miembros del anillo son heteroátomos seleccionados, cada uno en forma individual e independiente, del grupo integrado por N, O y S, y en donde los demás miembros del anillo son átomos de C; y, donde sea posible, cualquier miembro del anillo de N puede estar opcionalmente sustituido con alquilo C1-4; cualquier átomo de C del anillo puede estar opcionalmente sustituido, cada uno en forma individual e independiente, con un sustituyente seleccionado del grupo integrado por alquilo C1-4, alquenilo C2-6, cicloalquilo C3-7, hidroxi, alcoxi C1-4, halo, amino, ciano, trifluormetilo, hidroxialquilo C1-4, cianoalquilo C1-4, mono- o di(alquil C1-4)amino, aminoalquilo C1-4, mono- o di(alquil C1-4)aminoalquilo C1-4, arilalquilo C1-4, aminoalquenilo C2-6, mono- o di(alquil C1-4)aminoalquenilo C2-6, furanilo, tienilo, pirrolilo, oxazolilo, tiazolilo, imidazolilo, isoxazolilo, isotiazolilo, pirazolilo, oxadiazolilo, tiadiazolilo, triazolilo, tetrazolilo, arilo, hidroxicarbonilo, aminocarbonilo, alquiloxicarbonilo C1-4, mono- o di(alquil C1-4)aminocarbonilo, alquilcarbonilo C1-4, oxo, tio; y en donde cualquiera de los grupos anteriores furanilo, tienilo, pirrolilo, oxazolilo, tiazolilo, imidazolilo, isoxazolilo, isotiazolilo, pirazolilo, oxadiazolilo, tiadiazolilo y triazolilo pueden estar opcionalmente sustituidos con alquilo C1-4; Het2 es piridilo, pirimidinilo, pirazinilo, piridazinilo o triazinilo, en donde cualquier átomo de C del anillo de cada uno de dichos anillos aromáticos de 6 miembros que contienen N puede estar opcionalmente sustituido con un sustituyente seleccionado del grupo integrado por alquilo C1-4; (b) otro inhibidor de VIH. Reivindicacion 10: La combinacion de acuerdo con cualquiera de las reivindicaciones 1 a 6, donde el otro inhibidor de VIH está seleccionado entre: inhibidores de union, tales como, por ejemplo sulfato de dextrán, suramina, polianiones, CD4 soluble, PRO-542, BMS-806; inhibidores de fusion tales como por ejemplo, T20, T1249, RPR 103611, YK-FH312, IC 9564, 5-Hélice, D-péptido ADS-JI; inhibidores de la union del correceptor tales como, por ejemplo AMD 3100, AMD-3465, AMD 7049, AMD3451 (biciclámicos), TAK 779, T-22, ALX40-4C; SHC-C (SCH351125), SHC-D, PRO-140, RPR103611; inhibidores de RT tales como, por ejemplo, foscarnet y sus profármacos; nucleosidos RTI tales como, por ejemplo AZT, 3TC, DDC, tenofovir, DDI, D4T, abacavir, FTC, DAPD (amdoxovir), dOTC (BCH-10652), fozivedina, DPC 817; nucleotidos RTI tales como, por ejemplo PMEA, PMPA (TDF o tenofovir); NNRTI tales como, por ejemplo, nevirapina, delavirdina, efavirenz, CI TIBO 8 y 9 (tivirapina), lovirida, TMC-125, 4-[[4-[[4-(2-cianoetenil)-2,6-difenil]amino-2-pirimidinil]amino]benzonitrilo (R278474), dapivirina (R147681 o TMC120), MKC-442, UC 781, UC782, caprovirina, QM96521, GW420867X, DPC961, DPC963, DPC082, DPC083, calanolida A, SJ-3366, TSAO, TSAO 4"desaminado, MV150, MV026048, PNU-142721; inhibidores H de RNAsa tales como, por ejemplo, SP1093V, PDI26338; inhibidores de TAT tales como, por ejemplo RO-5-3335, K12, K37; inhibidores de integrasa tales como, por ejemplo, K 708906, L731988, S-1360; inhibidores de proteasa tales como, por ejemplo, amprenavir y fosamprenavir, ritonavir, nelfinavir, saquinavir, indinavir, lopinavir, palinavir, BMS 186316m, atazanavir, DPC 681, DPC 684, tipranavir, AG1776, mozenavir, DMP-323, GS3333, KNI-413, KNI-272, L754394, L756425, LG-71350, PD161374, PD1173606, PD177298, PD178350, PD178392, PNU 14135, TMC-114, ácido maslínico, U-140690; inhibidores de la glicosilacion tales como, por ejemplo castanoespermina, desoxinojirimicina; inhibidores de la entrada CGP64222. Reivindicacion 11: Una combinacion de acuerdo con cualquiera de las reivindicaciones 1 a 10, donde el otro inhibidor de VIH está seleccionado entre: (i) un inhibidor de fusion tal como, por ejemplo, T20, T1249, RPR103611, YK-FH312, IC 9564, 5-Hélice, D-péptido ADS-JI, enfuvirtida (ENF), GSK-873,140, PRO-542, SCH-417,690, TNX-355, maraviroc (UK-427,857); preferentemente uno o más inhibidores de fusion tales como, por ejemplo, enfuvirtida (ENF), GSK-873,140, PRO-542, SCH-417,690. TNX-355, maraviroc (UK-427,857); (ii) un nucleosido RTI tal como, por ejemplo AZT, 3TC, zalcitabina (ddC), ddl, d4T, abacavir (ABC), FTC, DAPD (amdoxovir), dOTC (BCH-10652), fozivudina, D-D4FC (DPC 817 o Reverset TM); alovudina (MIV-310 o FLT), elvucitabina (ACH-126,443); preferentemente uno o más nucleosidos RTI tales como, por ejemplo, AZT, 3TC, zalcitabina (ddC), ddl, d4T, abacavir (ABC), FTC, DAPD(amdoxovir), D-D4FC (DPC 817 o Reverset TM); alovudina (MIV-310 o FLT), elvucitabina (ACH-126,443); (iii) un nucleotido RTI tal como, por ejemplo, PMEA, PMPA, (TDF o tenofovir) o fumarato de tenofovir disoproxilo; preferentemente tenofovir o fumarato de tenofovir disoproxilo; (iv) un NNRTI tal como, por ejemplo, nevirapina, delavirdina, efavirenz, Cl TIBO 8 y 9 (tivirapina), lovirida, TMC-125, 4-[[4-[[4-(2-cianoetenil)-2,6-difenil]amino-2-pirimidinil]amino]benzonitrilo (TMC278 o R278474), dapivirina (R147681 o TMC 120), MKC-442, UC 781, UC782, caprovirina, QM96521, GW420867X, DPC 961, DPC963, DPC082, DPC083 (o BMS-561390), calanolida A, SJ-3366, TSAO, TSAO 4"desaminado, MV150, MV026048, PNU-142721; o preferentemente uno o más NNRTI tales como, por ejemplo, nevirapina, delavirdina, efavirenz, TMC125, TMC278, TMC120, caprovirina, DPC083, calanolida A; (v) un inhibidor de proteasa tal como, por ejemplo, amprenavir y fosamprenavir, lopinavir, ritonavir (como también combinaciones de ritonavir y lopinavir tales como Kaletra TM), nelfinavir, saquinavir, indinavir, palinavir, BMS186316, atazanavir, DPC 681, DPC 684, tipranavir, AG1776, mozenavir, DMP-323, GS3333, KNI-413, KNI-272, L754394, L756425, LG-71350, PD161374, PD1173606, PD177298, PD178390, PD178392, PNU 14135, TMC-114, ácido maslínico, U-140690; en particular uno o más inhibidores de proteasa tales como, por ejemplo, amprenavir y fosamprenavir, lopinavir, ritonavir (como también combinaciones de ritonavir y lopinavir), nelfinavir, saquinavir, indinavir, atazanavir, tipranavir, TMC-114.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04102173 | 2004-05-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR048962A1 true AR048962A1 (es) | 2006-06-14 |
Family
ID=34929108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050102016A AR048962A1 (es) | 2004-05-17 | 2005-05-17 | Combinaciones de 1- fenil-1,5 - dihidro - pirido - (3,2-b) indol -2- onas sustituidas y otros inhibidores de vih |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20070249655A1 (es) |
| EP (1) | EP1750708A1 (es) |
| JP (1) | JP2007538053A (es) |
| KR (1) | KR20070011588A (es) |
| CN (1) | CN1953751A (es) |
| AP (1) | AP2006003794A0 (es) |
| AR (1) | AR048962A1 (es) |
| AU (1) | AU2005244449A1 (es) |
| CA (1) | CA2563601A1 (es) |
| EA (1) | EA200602136A1 (es) |
| MX (1) | MXPA06013316A (es) |
| TW (1) | TW200612946A (es) |
| WO (1) | WO2005110411A1 (es) |
| ZA (1) | ZA200610588B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007088214A2 (en) * | 2006-02-03 | 2007-08-09 | Tibotec Pharmaceuticals Ltd. | Treating hiv infection, wherein hiv has a k65r mutation |
| MX2008012790A (es) * | 2006-04-03 | 2008-10-15 | Tibotec Pharm Ltd | 3,4-dihidro-imidazo[4,5-b]piridin-5-onas inhibidoras de virus de inmunodeficiencia humana. |
| WO2008037783A1 (en) * | 2006-09-29 | 2008-04-03 | Tibotec Pharmaceuticals Ltd. | Process for preparing 2-oxo-2,5-dihydro-1h-pyrido[3,2-b]indole-3-carbonitriles |
| WO2010115264A1 (en) * | 2009-04-09 | 2010-10-14 | Boehringer Ingelheim International Gmbh | Inhibitors of hiv replication |
| EA201201548A1 (ru) * | 2010-05-14 | 2013-05-30 | Эффектис Фармасьютиклз Аг | Новые способы получения p2x7r антагонистов |
| MX361607B (es) | 2010-06-23 | 2018-12-05 | Hunter Douglas Inc Star | Cubierta plástica de doble célula para aberturas arquitectónicas. |
| PL2748399T3 (pl) | 2011-08-26 | 2020-04-30 | Hunter Douglas Inc. | Pokrycie do otworu architektonicznego z panelem komórkowym z elementem pochłaniającym światło do wstrzymywania pasm świetlnych pomiędzy elementami komórkowymi |
| AU2012300274B2 (en) * | 2011-08-26 | 2017-06-29 | Sanford-Burnham Medical Research Institute | HIV replication inhibitors |
| AU2013361401C1 (en) * | 2012-12-21 | 2018-08-09 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| US10512633B2 (en) | 2014-10-26 | 2019-12-24 | King Abdullah University Of Science And Technology | Alkaloids from sponge, scaffolds for the inhibition of human immunodeficiency virus (HIV) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002059123A2 (en) * | 2000-12-18 | 2002-08-01 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Benzoylalkylindolepyridinium compounds and pharmaceutical compositions comprising such compounds |
| US20020182151A1 (en) * | 2000-12-18 | 2002-12-05 | The Government Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Services | Benzoylalkylindolepyridinium componds and pharmaceutical compositions comprising such compounds |
| US7608726B2 (en) * | 2002-11-15 | 2009-10-27 | Tibotec Pharmaceuticals Ltd. | Substituted indolepyridinium as anti-infective compounds |
-
2005
- 2005-05-17 MX MXPA06013316A patent/MXPA06013316A/es unknown
- 2005-05-17 AP AP2006003794A patent/AP2006003794A0/xx unknown
- 2005-05-17 US US11/569,111 patent/US20070249655A1/en not_active Abandoned
- 2005-05-17 CA CA002563601A patent/CA2563601A1/en not_active Abandoned
- 2005-05-17 EP EP05747916A patent/EP1750708A1/en not_active Withdrawn
- 2005-05-17 AU AU2005244449A patent/AU2005244449A1/en not_active Abandoned
- 2005-05-17 JP JP2007517256A patent/JP2007538053A/ja not_active Withdrawn
- 2005-05-17 EA EA200602136A patent/EA200602136A1/ru unknown
- 2005-05-17 WO PCT/EP2005/052266 patent/WO2005110411A1/en not_active Ceased
- 2005-05-17 TW TW094116035A patent/TW200612946A/zh unknown
- 2005-05-17 AR ARP050102016A patent/AR048962A1/es not_active Application Discontinuation
- 2005-05-17 KR KR1020067025921A patent/KR20070011588A/ko not_active Ceased
- 2005-05-17 CN CNA200580015688XA patent/CN1953751A/zh active Pending
-
2006
- 2006-12-15 ZA ZA200610588A patent/ZA200610588B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA200602136A1 (ru) | 2007-04-27 |
| WO2005110411A1 (en) | 2005-11-24 |
| EP1750708A1 (en) | 2007-02-14 |
| US20070249655A1 (en) | 2007-10-25 |
| CA2563601A1 (en) | 2005-11-24 |
| AP2006003794A0 (en) | 2006-10-31 |
| AU2005244449A1 (en) | 2005-11-24 |
| CN1953751A (zh) | 2007-04-25 |
| ZA200610588B (en) | 2008-06-25 |
| MXPA06013316A (es) | 2007-02-02 |
| TW200612946A (en) | 2006-05-01 |
| KR20070011588A (ko) | 2007-01-24 |
| JP2007538053A (ja) | 2007-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR048962A1 (es) | Combinaciones de 1- fenil-1,5 - dihidro - pirido - (3,2-b) indol -2- onas sustituidas y otros inhibidores de vih | |
| AR035664A1 (es) | Imidazo[4,5-c]quinolin-4-aminas y tetrahidroimidazo[4,5-c]quinolin-4-aminas, composiciones farmaceuticas que las comprenden, uso de dichos compuestos en la preparacion de medicamentos, e intermediarios utiles en la sintesis de dichos compuestos | |
| PE20151787A1 (es) | Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih | |
| AR070925A1 (es) | 4- hidroxipirimidina -5- carboxamida sustituidas, un procedimiento para el tratamiento preventivo de anemia, procedimiento para potenciar la produccion endogena de eritropoyetina, uso del compuesto en la fabricacion de un medicamento y composicion farmaceutica | |
| CU20190018A7 (es) | Compuestos inhibidores de los receptores endosomales tipo peaje | |
| UY36112A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| TW201113281A (en) | Compounds and compositions as TLR activity modulators | |
| DOP2018000153A (es) | Derivados de 4-amino-2-(1h-pirazolo[3,4-b]piridina-3-il)-6-oxo-6,7-dihidro-5h-pirrolo[2,3-d] pirimidina y los respectivos derivados de (1h-indazol-3-il) como moduladores cgmp para el tratamiento de enfermedades cardiovasculares | |
| UY33078A (es) | Derivados de imidazoquinolina | |
| AR049126A1 (es) | Derivados de 5, 6, 7, 8 - tetrahidroimidazo[1,5a]piridina con actividad inhibitoria de la aldosterona sintasa, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del hiperaldosterismo y del sindrome de cushing. | |
| CO2018002829A2 (es) | Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) | |
| HRP20150825T1 (hr) | Imidazo[1,2,-a]piridinski derivati kao inhibitori fgfr kinaze za uporabu u terapiji | |
| PE20181298A1 (es) | Inhibidores de bromodominio bivalentes y usos de los mismos | |
| GT201400301A (es) | 7h-pirrolo [2,3-d] pirimidinas-4- ( aminho-substituidas) novedosas como inhibidores de lrrk2 | |
| BR112015022294A2 (pt) | 2-azabiciclos substituídos e seu uso como moduladores de receptor de orexina | |
| PE20211768A1 (es) | Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmaceuticas y su uso | |
| ES2985591T3 (es) | Ligandos de receptores tipo Toll | |
| AR084257A1 (es) | Compuestos reguladores del crecimiento de plantas | |
| BR112014033055A8 (pt) | Inibidores seletivos de delta pi3k | |
| CN102844047A (zh) | 含tlr活性调节剂的免疫原性组合物 | |
| BR112017023147A2 (pt) | azabenzimidazóis e seu uso como moduladores do receptor de ampa | |
| BR112017001726A2 (pt) | compostos de 6,7-di-hidropirazolo [1,5-a]pirazin-4(5h)-ona e seus usos como moduladores alostéricos negativos de receptores mglur2 | |
| AR072622A1 (es) | Derivados de imidazo[2,1-b][1,3,4]tiadiazol, composiciones farmaceuticas que los comprenden, metodo para prepararlos, y uso de los mismos para el tratamiento de tumores y otras enfermedades inducidas por quinasas | |
| BR112012014058A8 (pt) | Derivados de 3,4,4a,10b- tetraidro-1h- tiopirano[4,3-c]isoquinolina | |
| HN2012000217A (es) | Compuestos derivados de amido espirociclicos y sales farmaceuticamente aceptable de los mismos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |